by Barry101 | Aug 8, 2017 | Press Release
Advocacy Organization to Work with Health Canada with the Goal to Gain ApprovalPHILADELPHIA, Aug. 08, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) has announced that on Thursday, August 3, 2017 it participated in a meeting in Toronto, Canada with Canadian...
by Barry101 | Aug 4, 2017 | Press Release
Cytokine Signatures Could Lead to the First Empirical Measure of Disease Severity in Chronic Fatigue SyndromePHILADELPHIA, Aug. 04, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) said today that a new study led by a team of researchers from Stanford University may...
by Barry101 | Jul 10, 2017 | Press Release
12 Pancreatic Cancer Patients Receiving Ampligen® Immuno-Oncology Therapy in Early Access ProgramPHILADELPHIA, July 10, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) announced that 12 pancreatic patients are currently undergoing treatment with single-agent...
by Barry101 | May 31, 2017 | Press Release
Joseph C. Horvath, M.D., Named Deputy Chief Medical Officer to Oversee Ampligen European Pancreatic Cancer Programs PHILADELPHIA, May 31, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) (“Hemispherx” or the “Company”) announced today that it...
by Barry101 | May 31, 2017 | Press Release
Promotes Carol Smith, Ph.D., to Chief Manufacturing Officer and Deputy Chief Scientific OfficerPHILADELPHIA, May 31, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) (“Hemispherx” or the “Company”) announced today that it continues to build its...
by Barry101 | May 15, 2017 | Press Release
The company has generated revenues from the lots of newly manufactured AmpligenPHILADELPHIA, May 15, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2017. The net loss was approximately $2,821,000...
